Related Experiment Video
Updated: May 13, 2026
A Protocol to Evaluate and Quantify Retinal Pigmented Epithelium Pathologies in Mouse Models of Age-Related Macular Degeneration
Published on: March 10, 2023
Potential Efficacy of Metformin for Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
Matthew D Huh1,2, Simon N Le1, Kieran S O'Brien1,3
1Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
Topic:
Metformin, a widely used diabetes medication, has shown potential for treating age-related macular degeneration (AMD) due to its antioxidative, anti-inflammatory, and antiangiogenic properties. This study aims to systematically review and analyze the efficacy of metformin in reducing AMD prevalence.
Clinical Relevance:
Metformin's potential to serve as a treatment for AMD could significantly reduce the burden of vision loss, offering a cost-effective and widely accessible solution.
Methods:
A systematic search was conducted in OVID Embase, OVID MEDLINE, Cochrane Library, and Web of Science databases on May 2, 2024. Both observational and interventional studies were included if they involved oral metformin use before AMD diagnosis. Data were extracted and analyzed using a random-effects model meta-analysis, with subgroup analyses based on study design, AMD subtype, sex, and metformin dosage.
Results:
Eighteen observational studies were identified, which together included a total of 2 683 234 individuals. Nine studies had a case-control design, 7 were retrospective cohort studies, and 2 were cross-sectional studies. The meta-analysis revealed a significant reduction in the odds of AMD among metformin users (pooled odds ratio [OR] = 0.86, 95% confidence interval = 0.79-0.93, P = 0.0002, I2 = 90%). The association was significant in both patients with diabetes (pooled OR = 0.89) and without diabetes (pooled OR = 0.70), although only 2 studies reported nondiabetic ORs. Dose-response analysis revealed significant protective effects at low doses. Sensitivity analysis indicated that the removal of an outlier study did not alter the overall effect. Bias analysis using the Risk of Bias in Nonrandomized Studies of Interventions tool revealed significant risks of bias, particularly due to confounding.
Conclusion:
Although the current evidence suggests a potential protective role of metformin in AMD, all studies showing an effect of metformin have been observational and thus subject to bias. Randomized clinical trials are needed to determine the effectiveness of metformin for preventing the onset of AMD.
Financial Disclosures:
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Insights
Metformin may reduce the risk of age-related macular degeneration (AMD). This systematic review found a lower odds of AMD in metformin users, but more research is needed.
Area of Science:
- Ophthalmology
- Pharmacology
- Gerontology
Background:
- Metformin, a common diabetes drug, possesses antioxidant, anti-inflammatory, and antiangiogenic properties.
- These properties suggest potential therapeutic benefits for age-related macular degeneration (AMD).
Purpose of the Study:
- To systematically review and analyze the efficacy of metformin in reducing the prevalence of age-related macular degeneration (AMD).
Main Methods:
- A systematic search of Embase, MEDLINE, Cochrane Library, and Web of Science databases was performed.
- Included studies involved oral metformin use prior to AMD diagnosis; data were meta-analyzed using a random-effects model.
- Subgroup analyses considered study design, AMD subtype, sex, and metformin dosage.
Main Results:
- Eighteen observational studies with over 2.6 million participants were analyzed.
- Metformin use was associated with a significant reduction in AMD odds (pooled OR = 0.86).
- Protective effects were observed in both diabetic and non-diabetic individuals, particularly at lower metformin doses.
Conclusions:
- Current evidence suggests a potential protective role for metformin against AMD.
- However, all included studies were observational and carried risks of bias, particularly confounding.
- Randomized clinical trials are essential to confirm metformin's effectiveness in preventing AMD onset.
More Related Videos
08:54Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
Published on: May 26, 2023
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Related Concept Videos
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism